Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Thursday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has supported label update for weight-loss drug Ozempic to include kidney disease risk ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today and set a price target of $155.00.

On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to ...

A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

Denmark’s central bank followed its European counterpart with a quarter-point interest-rate cut to defend the krone’s peg to ...

As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily lo Bagsværd, Denmark, 2 December 2024 – On 11 November 2024 ...

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...